Saturday 17 October 2026
Export PEPG’s income statement to Excel — free account
PepGen, Inc.
PEPG Healthcare Biotechnology
In the quarter to June 2026, EPS grew 62.9% and free cash flow grew 33.0%, each against the same quarter a year earlier.
2.60
0.07
+2.77%
Follow PEPG
| Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|
Current Ratio |
11.58 | 12.31 | 13.56 | 9.88 | 6.43 | 7.41 | 11.94 |
Net Debt/EBITDA |
2.80 | 5.53 | 4.93 | 2.68 | 1.31 | 1.25 | 1.64 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.66 | 0.41 | 0.83 | 0.86 | 0.88 | 0.92 | 0.91 |
Capex/Depreciation |
0.00 | (0.07) | (2.81) | (7.62) | (4.13) | (0.37) | (0.09) |
Interest Coverage |
(451.33) | — | — | — | — | — | — |
| 0.00% | 327.08% | 141.93% | (93.67%) | (54.59%) | (79.26%) | (67.39%) | |
| 0.00% | (54.96%) | (35.36%) | (38.28%) | (43.62%) | (61.23%) | (55.21%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(34.81%) | (41.59%) | (20.94%) | (40.51%) | (78.70%) | (81.22%) | (63.94%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(0.04) | (1.91) | (25.64) | (4.03) | (3.01) | (2.62) | (1.94) |
Cash per Share |
0.16 | 11.24 | 147.50 | 11.62 | 4.64 | 3.81 | 3.52 |
Shareholders Equity per Share |
0.17 | (7.31) | (35.61) | 11.49 | 4.56 | 3.76 | 3.49 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.17 | (7.31) | (35.61) | 11.49 | 4.56 | 3.76 | 3.49 |
Free Cash Flow |
(0.88) | (1.66) | (23.10) | (63.02) | (71.60) | (82.87) | (81.90) |
Working Capital |
3.45 | 9.48 | 129.67 | 167.26 | 95.15 | 107.07 | 138.32 |
Capital Expenditures |
(0.03) | (0.01) | (0.50) | (3.75) | (2.60) | (0.50) | (0.26) |
Net Current Asset Value |
3.45 | (6.68) | (35.74) | 148.27 | 78.05 | 91.50 | 124.50 |
| Other line items | |||||||
Quick Ratio |
11.41 | 12.15 | 13.34 | 9.65 | 6.30 | 7.20 | 11.74 |
Depreciation/Fixed assets |
0.25 | 0.34 | 0.28 | 0.15 | 0.13 | 0.36 | 1.54 |
Cash ROIC |
(12.03%) | (48.57%) | (22.91%) | (17.44%) | (32.72%) | (34.70%) | (27.68%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
485.52 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.04) | (1.90) | (25.08) | (3.79) | (2.90) | (2.61) | (1.93) |
Capex per Share |
0.00 | (0.01) | (0.55) | (0.24) | (0.11) | (0.02) | (0.01) |
Average Receivables |
— | 0.32 | 2.58 | 2.40 | — | — | — |
Average Payables |
— | 0.43 | 1.98 | 2.30 | 1.18 | 1.38 | 1.29 |
Average Assets |
— | 7.42 | 77.14 | 180.54 | 180.25 | 146.97 | 162.40 |
Average Common Equity |
— | (1.25) | (19.22) | 73.77 | 144.03 | 113.52 | 133.03 |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates